GLP-1 Dosing Frequency: Weekly Schedules & Personalization

Last reviewed: May 31, 2026

Last updated: May 31, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Most GLP-1 receptor agonists are administered once weekly via subcutaneous injection, though daily oral formulations also exist. Standard semaglutide dosing escalates from 0.25 mg weekly to a maintenance range of 2.4 mg weekly over 16 weeks, while tirzepatide follows a similar titration structure with higher potency per dose.

Choosing the right dosing frequency requires more than reading a label. Your metabolism, cardiovascular health, gastrointestinal tolerance, and underlying genetic factors all influence which schedule works best. This article helps you understand dosing protocols and why personalized assessment matters for sustainable, effective treatment.

Standard GLP-1 Dosing Schedules Across Formulations

Injectable GLP-1 agonists dominate clinical practice due to higher potency and once-weekly convenience. Semaglutide begins at 0.25 mg weekly, increasing by 0.25 mg every four weeks until reaching 2.4 mg maintenance. Tirzepatide uses a similar escalation but with higher baseline efficacy, often reaching 15 mg weekly.

Oral semaglutide tablets offer daily dosing flexibility but require specific administration protocols—taken on an empty stomach 30 minutes before food. Daily oral tirzepatide follows comparable timing. Both oral formulations achieve lower peak concentrations than injections, requiring higher doses and potentially longer titration periods to match therapeutic effect.

Dosing Frequency Comparison: Injection vs. Oral vs. Microdose Protocols

Treatment frequency impacts adherence, side-effect profiles, and metabolic response patterns. The table below compares standard maintenance schedules, bioavailability, and typical duration of action across primary GLP-1 formulations used in clinical practice.

Your provider may recommend microdose protocols—lower-frequency or lower-dose variants—if you have specific health considerations, previous medication sensitivities, or genetic variants affecting peptide receptor expression. This personalized approach can improve tolerability while maintaining efficacy.

Formulation Type	Typical Frequency	Maintenance Dose	Peak Effect Timing
Weekly Injectable Semaglutide	Once weekly	2.4 mg SC	1–3 days
Weekly Injectable Tirzepatide	Once weekly	10–15 mg SC	2–5 days
Daily Oral Semaglutide	Once daily	7–14 mg PO	1–4 hours
Daily Oral Tirzepatide	Once daily	10–15 mg PO	2–6 hours
Microdose GLP-1 Protocol	Variable (daily/weekly)	Lower than standard	Individualized

How Biomarkers & Genetic Factors Shape Optimal Dosing Frequency

Dosing frequency is not purely a scheduling convenience—it reflects how your body processes and responds to GLP-1 signaling. Baseline metrics including fasting glucose, insulin sensitivity, lipid profiles, and inflammatory markers help providers determine whether standard escalation or modified protocols suit your physiology best.

Genetic variations in GLP-1 receptor expression, glucose metabolism genes, and appetite regulation pathways influence how quickly you reach therapeutic response and tolerability thresholds. Some individuals benefit from slower titration or microdose approaches due to genetic predispositions affecting peptide signaling efficiency.

Safety Considerations & Who Should Start with Modified Dosing

Rapid dose escalation can trigger gastrointestinal side effects, nausea, and pancreatic concerns in susceptible individuals. Patients with prior pancreatitis, severe gastroparesis, kidney disease, or thyroid cancer history typically require extended titration or lower maintenance targets. Cardiovascular disease, polypharmacy, and older age may also warrant conservative frequency adjustments.

A qualified provider assesses your full clinical picture—medication interactions, organ function, baseline metabolic state—before recommending standard versus personalized dosing schedules. This evaluation should occur before starting treatment and during follow-up, especially if side effects or inadequate response emerges.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines key variants in GLP-1 receptor genes, glucose-insulin pathways, and appetite-regulating loci—including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313. These predispositions may help provide context about how your genetic background influences peptide signaling efficiency and metabolic response patterns, supporting a more informed conversation with your provider about whether standard weekly dosing or a modified protocol aligns with your biology.

The genetic test reveals inherited predispositions in peptide pathways—not exact medication response or dosing requirements. Some genetic variants correlate with variations in GLP-1 receptor density, glucose processing speed, or appetite sensitivity, but individual response remains influenced by age, lifestyle, comorbidities, and medication interactions. This information should be interpreted with a qualified healthcare provider as part of comprehensive treatment planning.

When combined with clinical assessment, genetic context can help your provider tailor initial dosing strategy, predict tolerability challenges, and adjust frequency more thoughtfully. PlexusDx compounded semaglutide, tirzepatide, and microdose GLP-1 options support flexible personalization—available as weekly injections, daily tablets, or specially formulated protocols—ensuring your treatment frequency truly fits your metabolic and genetic profile.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Oral starts at from $209/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.